A different room, a different population
Human phase 3a · REDEFINE 2; published June 22, 2025
What did the separate trial in people with diabetes find?
Subject One tries to carry the previous room’s chart through the next doorway. Doctide points to the name above it: a different population. The visitor rolls up the chart and opens a clean notebook. Nobody crosses from one trial into another.
What changes here
The diabetes trial also favored CagriSema over placebo; its results and harms belong to its own population. [1]
Read the study details & dates
NCT05394519 · Primary results published
REDEFINE 2 randomized 1,206 adults with type 2 diabetes, BMI ≥27 and HbA1c 7–10%: 904 CagriSema, 302 placebo. This double-blind phase 3a study used weekly subcutaneous cagrilintide–semaglutide (2.4 mg each target), plus lifestyle intervention. Treatment-policy weight change was −13.7% versus −3.4% (difference −10.4 points; 95% CI −11.2 to −9.5). Serious adverse events occurred in 10.4% versus 12.9%; gastrointestinal events in 72.5% versus 34.4%. [1]
What this does not establish
The main report gives adjudicated causes, not verified treatment attribution for each death. Different populations prevent a simple efficacy ranking against REDEFINE 1.
Original sources
Sources reviewed November 3, 2026. Sponsor material is labeled; event dates are distinct from this editorial date. Trial identifiers identify the studies, not an invitation to enroll.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story